Conformational switching and spatial heterogeneity: Decoding SERPINE1/PAI-1as a multifaceted driver of tumor progression and therapy resistance.

Plasminogen activator inhibitor-1 (PAI-1), a central fibrinolytic regulator encoded by the SERPINE1 gene, is increasingly recognized as a context-dependent molecular hub in tumor biology. Despite its canonical protease-inhibitory role, elevated PAI-1 levels are associated with metastasis and poor prognosis in many malignancies, creating an apparent functional paradox. This review examines how reactive-center-loop conformational transitions, binding partners, cellular source, and anatomical compartment can alter SERPINE1 output. We compare tissue-specific circuits across lung, breast, colorectal, and neural tumors and incorporate recent evidence that SERPINE1 loss can engage distinct p53/SMAD3-MCM3, uPAR-ERK/p38, and HSP90α-p38-MMP-1 modules. We also evaluate a testable convergence model linking GDNF-GFRα1-RET signaling to SERPINE1 regulation and downstream PAI-1-associated pathways in neural tumors, while emphasizing that a direct causal connection has not yet been demonstrated. Finally, we frame the concentration-dependent inflammation-invasion switch as a working hypothesis and assess therapeutic strategies, including TM5614 and ACT001, in relation to tumor context and hemostatic safety.